. Nevertheless, if it were possible to generate more aligned science between academia and industry, as well as management teams who are experienced to navigate the intricate maze, it may be possible to also benefit investors as well.
Students and early career professionals without any exposure to the industry may not understand the major differences between programs and how they are rooted in different disciplines, and therefore end up on a course that does not align with their career goals.
If professionals are unwilling to return to academia, it would be wise for students to gain hands-on experience via industrial internships in the early stages of the educational process and to open collaborations later in their careers. One notable example is Northeastern University in Boston, where the new Roux Institute integrates research, venture and entrepreneurship.
This curriculum can only be created with input from the entire ecosystem. This may mean that courses are taught with modules from different faculties and that basic introduction courses must be developed. Facilities are already available within many establishments; thus, this is a logistical issue rather than a resource one, lowering the bar for change.
This would continue to bring new first-in-class assets into the pipeline, create potential future niche pharma players and move drug development away from ‘me too’ development and the dominance of a handful of companies. This could also allow for new drugs to be developed in much-needed areas, such as neglected tropical diseases and other infectious diseases. In this way, it would propel a new wave of pipeline drugs, biotech and entrepreneurs.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: IntEngineering - 🏆 287. / 63 続きを読む »